The Pharmaceutical industry is faced with increasing costs to move a compound from bench to market and then faced with shorter periods of IP protection as well as increased efforts to control and reduce pricing. All of this has a negative impact on earnings, which jeopardize future development programs.
Through the initiation of a proper launch sequence of a compound within countries a company can maximize the ROI. Decisions must made prior to a compound entering phase III as the regulatory approval process differs across many regions and the timing of initiation of clinical trials within a country can affect when the compound can gain regulatory approval aligned to the optimal launch sequence and maximization of ROI.
Through this discussion, attendees will learn how to apply advanced optimization analytics, used to navigate through international reference pricing and develop launch sequences, in the clinical trial process to achieve enhanced revenues.
Key Learning Objectives
- Discuss the use of advanced optimization analytics to determine optimal launch sequences
- Illustrate how to apply these analytics to the clinical trial process
- Share examples of the impact of the use of the SAS optimization tool on real world compounds revenue
Audience
- CEO
- Chief of Research
- Head
- VP and Directors of Clinical Research
- Drug Development
- Clinical Trials
- Clinical Research Services
- Clinical Operations
- Clinical Data Management
